IOVA iovance.com: Enterprise Value to EBITDA Ratio

Graphic logo of Iovance Biotherapeutics, Inc. (IOVA)

The current EV/EBITDA multiple correlates with Iovance Biotherapeutics (IOVA) revenues from exclusive sales of AMTAGVI for the treatment of melanoma, while 0.00 serves as the base value of the parameter. Iovance Biotherapeutics (IOVA) complies with environmental regulations regarding the processing of biomaterials in its laboratories. Its first-mover status in cell therapy provides the company with multi-year patent control within the complex oncology segment.

Iovance - IOVA Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/13/2026)

Summary analytical data breakdowns for iovance.com (IOVA)

- stock price and consensus target price:
Stock Quotes Iovance|IOVA - Average Forecast Price
- company stock capitalization data:
Market Valuation Iovance Corp|IOVA - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Iovance Biotherapeutics|IOVA - Book Valuation of Business|Market Value to Book Value Ratio iovance.com|IOVA - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Iovance Biotherapeutics|IOVA - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Iovance Biotherapeutics, Inc.|IOVA - Company Aggregate Debts|Debt to Book Capitalization Ratio Iovance Corp|IOVA - Company Long-Term Indebtedness|Company Short-Term Debt Iovance Biotherapeutics|Quick Liquidity Indicator iovance.com
- financial results and valuation multiples details:
IOVA - Annual Net Income|Future Profit Iovance Biotherapeutics|IOVA - Market Price to Net Income Ratio|Forward P/E Multiple Iovance Biotherapeutics|IOVA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Iovance Corp|IOVA - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Iovance Biotherapeutics|IOVA - Earnings per share for the trailing year|Quarterly EPS earnings growth iovance.com|IOVA - Earnings growth in current year|Net earnings per share growth forecast for next year Iovance Biotherapeutics
- sales volume and revenue indicators:
IOVA - Company Annual Revenue|Company Future Sales Volume Iovance|IOVA - Price to Sales|Forward P/S Multiple Iovance Corp
Fundamental company analysis:IOVA (Iovance)
Original product of Iovance Biotherapeutics Inc

For Iovance Biotherapeutics (IOVA), which focuses on independently launching cell therapy without M&A, the business's EV/EBITDA ratio serves as a filter for model viability given the capital-intensive nature of the industry. The ratio of enterprise value to earnings before interest, taxes, depreciation, and amortization allows for the filtering of speculative noise, revealing whether the asset is truly undervalued or if there is a risk of capital freeze in the event of margin compression.

Competitor analysis for Iovance Biotherapeutics

ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Immatics Corp|Enterprise Value to EBITDA Ratio Xencor Inc. (XNCR)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Compass Therapeutics (CMPX)|Enterprise Value to EBITDA Ratio replimune.com REPL|Lyell Immunopharma, Inc. - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Innate Pharma SA IPHA|PYXS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CGEN (Compugen Ltd.) - Enterprise Value to Operating Income Before Depreciation|IO Biotech, Inc. (IOBT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA sutrobio.com (STRO)|Enterprise Value to EBITDA Ratio INKT|HOWL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Biotech|Liminatus Pharma Corp (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|Kineta, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio neximmune.com NEXI|turnstonebio.com (TSBX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Vaccinex Inc. (VCNX)|Enterprise Value to EBITDA Ratio HARP